Submit Manuscript  

Article Details


Cyclin-Dependent Kinase 4/6 (Cdk4/6) Inhibitors: Perspectives in Cancer Therapy and Imaging

[ Vol. 10 , Issue. 6 ]

Author(s):

F. Graf, B. Mosch, L. Koehler, R. Bergmann, F. Wuest and J. Pietzsch   Pages 527 - 539 ( 13 )

Abstract:


Cyclin-dependent kinases 4 and 6 (Cdk4/6) are important components of cell cycle activation and control in early G1 phase. Both enzymes and their regulators, e.g., cyclins, play critical roles in embryogenesis, homeostasis, and cancerogenesis. Cdk4/6 are attractive targets for cancer treatment. Recently, numerous selective small molecule inhibitors of Cdk4/6 have been developed. The potential of Cdk4/6 inhibitors, particularly, pyrido[2,3-d]pyrimidine derivatives, as both anti-cancer drugs and 124I- and 18F-radiolabeled tracers for cancer imaging using positron emission tomography is discussed.

Keywords:

Cell cycle regulation, pyrido[2,3-d]pyrimidine, iodine-124, fluorine-18, radiolabeling, positron emission tomography

Affiliation:

Department of Radiopharmaceutical Biology, Institute of Radiopharmacy, Research Center Dresden-Rossendorf, P.O.-Box 510119, 01314 Dresden, Germany.



Read Full-Text article